Eloxx Pharmaceuticals Inc. Common Stock (ELOX)
Stock · NASDAQ · Health Care
$12.88as of 10/16/2026
Price chart
Active signals
High Beta100.0%
Support Confirmation0.0%Support level
$11.16
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
About ELOX
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alpo…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 10
- Website
- www.eloxxpharma.com/
Fundamentals
- 1-day range
- $12$14.24
- Market cap
- $71.48M
- P/E (trailing)
- —
- P/E (forward)
- -19.30
- EPS (trailing)
- $-7.06
- Dividend yield
- —
- Beta
- 3.37
- Avg. volume
- 44.2K
- Dividend pay date
- December 20, 2017
52-week range
$0$23.4
Forecasts
4 analyst ratings
Buy 89%
Hold 11%
Sell 0%
1-year price forecast
High
$43
+234.0%
Median
$39
+202.9%
Low
$32
+148.5%
Eloxx Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ELOXEloxx Pharmaceuticals Inc. Common Stock$13.03▼ 4.89%Market cap $71.48MP/E —$0$23.4
- CSBRChampions Oncology Inc. Common Stock$4.7▼ 1.88%Market cap $72.11MP/E —$4.59$8.31
- LONALeonaBio Inc. Common Stock$5.2▼ 1.70%Market cap $73.36MP/E —$2.21$14.21
- ATRAAtara Biotherapeutics Inc. Common Stock$9.18▼ 4.87%Market cap $74.33MP/E —$3.92$19.15
- CRDFCardiff Oncology Inc. Common Stock$0.9▼ 7.22%Market cap $74.71MP/E —$0.7566$3.31
- IMAImageneBio Inc. Common Stock$4.04▲ 0.25%Market cap $63.50MP/E —$3.9$9.1
- GNTAGenenta Science S.p.A. American Depositary Shares$0.675▲ 0.90%Market cap $63.16MP/E —$0.55$10
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ELOX Eloxx Pharmaceuticals Inc. Common Stock | $71.48M | — | $13.03 | ▼ 4.89% | $0$23.4 |
| CSBR Champions Oncology Inc. Common Stock | $72.11M | — | $4.7 | ▼ 1.88% | $4.59$8.31 |
| LONA LeonaBio Inc. Common Stock | $73.36M | — | $5.2 | ▼ 1.70% | $2.21$14.21 |
| ATRA Atara Biotherapeutics Inc. Common Stock | $74.33M | — | $9.18 | ▼ 4.87% | $3.92$19.15 |
| CRDF Cardiff Oncology Inc. Common Stock | $74.71M | — | $0.9 | ▼ 7.22% | $0.7566$3.31 |
| IMA ImageneBio Inc. Common Stock | $63.50M | — | $4.04 | ▲ 0.25% | $3.9$9.1 |
| GNTA Genenta Science S.p.A. American Depositary Shares | $63.16M | — | $0.675 | ▲ 0.90% | $0.55$10 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- This Eloxx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursdaybenzinga · 10/15/2026
- 12 Health Care Stocks Moving In Monday's Pre-Market SessionBenzinga · 9/28/2026
- Leerink Partners Initiates Coverage On Eloxx Pharma with Outperform Rating, Announces Price Target of $32Benzinga · 9/18/2026
- Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport SyndromeYahoo · 9/11/2026
Insider Activity
Insider Actions →Acquired
968.6K
Disposed
1.36M
- Domicilium Real Estate Fund III LP · June 10, 2026 · J361.6K
- Domicilium Real Estate Fund III LP · June 10, 2026 · J238.4K
- Sumit Aggarwal · June 10, 2026 · Grant328.8K
- Webster Stephen W · June 8, 2026 · Grant13.6K
- Alan Edmund Walts · June 8, 2026 · Grant8.6K
- Kjellson Nina S · June 8, 2026 · Grant13.6K
- Steven D. Rubin · June 8, 2026 · Grant4.0K
- Domicilium Real Estate Fund III LP · May 27, 2026 · J113.6K
- Coastlands Capital LP · May 27, 2026 · J1.25M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Eloxx Pharmaceuticals Included in Pre-Market Movers List
Eloxx Pharmaceuticals was featured in a recent roundup of healthcare stocks showing movement during Monday's pre-market session. The company currently trades with a low trailing P/E ratio of 5.3, which is significantly below the average analyst target price of $38.25. This inclusion highlights current market attention on the stock, though the specific drivers for the pre-market activity are not detailed in the provided report.
Eloxx Pharmaceuticals Included in Pre-Market Movers List. Eloxx Pharmaceuticals was featured in a recent roundup of healthcare stocks showing movement during Monday's pre-market session. The company currently trades with a low trailing P/E ratio of 5.3, which is significantly below the average analyst target price of $38.25. This inclusion highlights current market attention on the stock, though the specific drivers for the pre-market activity are not detailed in the provided report.